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Introduction
The acute respiratory distress syndrome (ARDS) is a common and often fatal syndrome characterized by neutrophilic inflammation. In ARDS, and experimental models of acute lung injury (ALI), an exuberant inflammatory response with release of proteases and other toxic mediators from activated leukocytes leads to tissue damage, increased permeability of the alveolar-capillary barrier and the formation of protein-rich lung edema. 1 which collectively are pro-resolution properties. 13, 14 Production of lipoxins requires transcellular biosynthesis, with leukocytes, platelets, and tissue resident cells having important roles. 12, 15 Aspirin-triggered lipoxin (ATL) shares the potent anti-inflammatory actions of lipoxins but is more resistant to metabolic inactivation. 16 The anti-inflammatory, pro-resolving properties of both LXA 4 and 15(R)-epi-LXA 4 are mediated through the formyl peptide receptor type 2 (FPR2, termed Fpr2/3 in the mouse), also called the lipoxin A 4 receptor (ALX), 17 which is expressed in a variety of cell types including endothelial cells and myeloid lineages. 17, 18 In addition to native lipoxins and ATL, ALX recognizes a diverse array of bioactive mediators including annexin A1, resolvin D1, and SAA. 17, 19 Recent work has elucidated the molecular mechanisms behind the dual actions of ALX (pro-vs. anti-inflammatory responses), which is determined by unique receptor dimerization patterns induced by specific ligands. 20 Here, we demonstrate the role of ATL in regulating leukocyte-platelet aggregation, and consequently lung injury, in both direct and indirect experimental models of ALI: Intratracheal instillation of lipopolysaccharide (LPS) and a two-event model of transfusion-related acute lung injury (TRALI). 21 We present evidence that platelets have a central role in producing pulmonary inflammation and injury based on critical interactions with neutrophils that are regulated by ATL.
Methods

Reagents.
The following reagents were used: aspirin (acetylsalicylic acid); LPS from whole lungs were digested 21 followed by the same general protocol described above. All data were analyzed using FlowJo software (TreeStar).
In vitro neutrophil-platelet aggregate experiments. Whole blood was collected from C57BL/6
WT and Fpr2/3 -/-mice into ACD, and used to isolate platelets. 23 Bone-marrow neutrophils were isolated, as previously described. 24 
Results
Intratracheal LPS induces platelet sequestration and activation within the lungs and aspirin
attenuates these responses. To determine the role of platelets in experimental ALI, we used an intratracheal LPS model of lung injury. Immunohistochemistry for the platelet specific marker CD41, 48 hours after intra-tracheal LPS instillation (5 µg/g), revealed intense sequestration of platelets within LPS-injured lungs, compared to PBS-instilled control animals ( Figure 1A , B).
We cannot rule out that areas of particularly intense CD41 staining at vessel junctions could indicate the presence of megakaryocytes. CD41 protein expression in total lung digest was analyzed by Western blot, and confirmed the sequestration of platelets within the lungs of LPSchallenged animals ( Figure 1D ). Thromboxane A 2 is a marker of platelet activation and is rapidly hydrolyzed to its inactive stable metabolite, thromboxane B 2 (TXB 2 ). Plasma TXB 2 levels were increased after LPS challenge ( Figure 1E ). Pre-treatment with aspirin 24h and 2h before LPS CD41 immunohistochemistry of lungs after LPS challenge revealed intense sequestration of platelets within the pulmonary capillaries, but also suggested the presence of intra-alveolar 1 platelets ( Figure 1B inset) . To further test for intra-alveolar platelet accumulation, we probed for CD41 protein via Western blot analysis on cells obtained from BAL. CD41 protein was increased in BAL from LPS-challenged mice, compared to PBS controls ( Figure 2D ). We also used flow cytometry and a CD41 mAb to determine the presence of platelets in the BAL, and did not detect intra-alveolar platelets in control animals, but a sharp increase was detected after LPS challenge ( Figure 2E ). We tested for pulmonary hemorrhage as a potential cause of intraalveolar accumulation of platelets by measuring BAL hemoglobin and found a minimal increase in hemoglobin in the LPS-challenged animals (Supplemental Figure 1) . We detected significantly increased TXB 2 concentrations in the cell-free-BAL supernatant of LPS-treated mice, compared to controls ( Figure 2F ). These results demonstrate that platelets accumulate and are activated in the alveolar spaces after LPS challenge. Aspirin treatment yielded a significant reduction in both alveolar LPS-induced CD41 expression ( Figure 2D , E) and platelet activation ( Figure 2F ) and did not affect BAL hemoglobin measurements.
Leukocyte-platelet aggregates are present in the blood and alveolar spaces after LPS-challenge
and are reduced with aspirin treatment. We investigated the LPS-induced formation of leukocyte-platelet aggregates (LPA) in whole blood and BAL using flow cytometry. The gating strategies for whole blood and BAL are illustrated in Supplemental Figure 2A -B. Briefly, antibodies against the leukocyte-specific surface markers CD11b, Ly6G or Ly6C, in addition to the platelet-specific marker CD41, were used to identify monocyte-platelet aggregates (MPA), defined as CD11b + /Ly6C + /Ly6G -/CD41 + , and neutrophil-platelet aggregates (NPA), defined as Dynamic formation of NPA within the lung microcirculation. We used two-photon intravital lung microscopy 25 to determine the spatial and temporal formation of NPA within the pulmonary microcirculation at baseline and after LPS-induced ALI. To track platelets, Rosa26-LSLtdTomato mice were crossed with PF4-cre mice, 26 and in the peripheral blood of these mice, >99% of the tdTomato + events were also CD41 + (Supplemental Figure 3) . These mice were crossed with LysM-eGFP mice to facilitate neutrophil identification. Cascade-blue dextran was To determine whether elevated 15-epi-LXA 4 contributed to the decreased lung injury observed
after aspirin treatment, we tested the ALX (Fpr2/3) antagonist, Boc2. 27 The administration of Boc2 30min before aspirin treatment, and repeated 24h after LPS instillation, reversed the protective effects of aspirin on lung injury ( Figure 4C, D) . Additionally, Boc2 partially reversed the decrease in whole blood NPA after aspirin treatment ( Figure 4E ). Boc2 treatment alone (in the absence of aspirin) had no effect on LPS-induced lung inflammation or injury (data not shown). Also, Boc2 did not change the plasma 15-epi-LXA 4 concentrations of aspirin treated mice (data not shown). 
Effects of 15-epi-LXA 4 on LPS-induced lung injury.
To evaluate whether pharmacologic doses of 15-epi-LXA 4 can modulate LPS-induced lung injury, mice were treated with increasing doses of this lipid mediator. Intravenous administration of between 100-1500 ng of 15-epi-LXA 4 did not produce a significant change in BAL WBC counts or total protein after LPS challenge ( Figure   5A , B). However, doses of 5 µg resulted in a significant decrease in BAL WBCs ( Figure 5A ) and attenuated lung permeability ( Figure 5B ) and whole blood NPA formation ( Figure 5C ) in a similar manner to that observed with aspirin treatment.
To determine whether lipoxin receptor signaling on neutrophils and/or platelets mediated the protective effects observed after aspirin and 15-epi-LXA 4 treatment, we developed a co-culture system in which neutrophils and platelets, freshly isolated from WT or Fpr2/3 -/-mice, were incubated with LPS (5 ug/mL) to induce NPA formation. We observed a basal formation of NPA after a 1h incubation of WT neutrophils and platelets (1:100), which increased after LPS treatment ( Figure 5D ). Pre-treatment with 15-epi-LXA 4 (300 nM) significantly decreased LPSinduced NPA formation ( Figure 5D ). We next tested combinations of WT and Fpr2/3 -/-neutrophils and platelets, and observed that the presence of a functional lipoxin receptor was required on both neutrophils and platelets for 15-epi-LXA 4 to decrease NPA formation ( Figure   5D ).
Lipoxins enhance inflammatory resolution in TRALI.
We have previously demonstrated that aspirin treatment decreases platelet sequestration, lung vascular permeability and edema formation, and increases survival in an experimental TRALI model. 2, 24 Here, we investigated whether ATL was required for these effects. In a two-event model of TRALI, 21 Platelets are capable of rapidly responding to inflammatory stimuli, releasing preformed mediators and even synthesizing immune mediators from mRNA transferred from megakaryocytes.
28
Platelets and platelet microparticles 29 can bind to leukocytes and the endothelium, influencing the function of these cells during inflammation. Indeed, using lung intravital imaging, we have now shown that the lung is a site of de novo NPA formation under basal conditions. The unique structural features of the lung microcirculation that influence neutrophil trafficking, 30 and the proposed role of the lung in thrombopoiesis, 31 may enhance these interactions. With inflammation, we found an early and rapid increase in dynamic NPA formation in the lung microcirculation and many of these aggregates were ultimately detected in the alveolar spaces. Previous reports of NPA formation in inflammation have shown that neutrophils bound to the endothelium secondarily capture platelets, 32,33 but our direct imaging of the lung microcirculation reveals that these aggregates are mobile, and are eventually capable of migrating into the alveolar spaces. It has recently been described that the PF4-cre mouse is potentially leaky in non-megakaryocyte lineages, 44 however, in the peripheral blood we found that >99% of the PF4-cre driven tdTomato + events were platelet specific (CD41 + ).
There is a current lack of understanding of the regulation of LPA formation. Here, we propose that anti-inflammatory lipoxins and ATL specifically, regulate this process. Lipoxins and ATL exert potent anti-inflammatory and pro-resolution bio-actions. In particular, they block chemotaxis, adherence to microvasculature, inhibit NF-B activation in leukocytes, and block the release of pro-inflammatory cytokines such as IL-6, IL-8 and TNF-α. 16 ,34-37 A potential limitation of our study is that microgram quantities of ATL were required to limit lung injury in our experiments, whereas others have reported that nanogram amounts of pro-resolving lipid mediators are sufficient. 14 However, we treated with ATL at just two time points in our 48 hour LPS model, and more frequent dosing of ATL, which has a half-life of a few minutes, may have allowed for lower overall amounts. Also, we have not ruled out the contribution of other aspirintriggered lipid mediators, such as resolvins, but results from our pharmacologic experiments support a major role of ATL in mediating the protective effects of aspirin.
Others have shown protective effects of lipoxins in acute inflammation. LXA 4 and ATL were protective in an acid-induced ALI model through the modulation of neutrophil apoptosis. 38 ATL was also protective in mice challenged with LPS through a heme-oxygenase1-dependent mechanism. 39 Endogenous LXA 4 modulates ischemia-reperfusion injury in the gut, and Fpr2/3 -/-mice have more inflammation and injury compared to wild-type animals. 40 In this same study, NPA formation was investigated using chimeric experiments to test whether platelet or neutrophil Fpr2/3 was more important in aggregate development, and neutrophil Fpr2/3 was determined to be critical. 40 However, in our neutrophil-platelet aggregation assay, we found that neither neutrophil nor platelet Fpr2/3 is required for the formation of aggregates in response to LPS, but Fpr2/3 on both cells is required for lipoxin-mediated inhibition of NPA formation.
For the first time, we have shown the presence of platelets in the alveolar spaces in ALI. Others have shown in experimental allergic inflammation, that platelets migrate out of vessels and localize beneath airways 41 or into the synovial spaces in rheumatoid arthritis. 8 Platelets have also been observed by electron microscopy extravasating out of the lung vasculature in patients with ARDS. 42 In our studies, many of the platelets were bound to neutrophils, and the dynamics of NPA migration into the alveolar spaces after LPS challenge seems to occur hours after the very early formation of NPA in the lung vessels. More work is needed to determine the mechanisms of platelet transmigration in the lung, including the chemotactic stimuli for platelets, and whether transmigration is facilitated by tethering to neutrophils or occurs independently.
Notably, our assays could have detected intact platelets or platelet microparticles in the alveolar spaces, and the specific role of platelet microparticles in lung inflammation should be addressed in future studies.
We previously reported that aspirin is protective in a two-event model of TRALI by decreasing platelet sequestration and activation and NET formation. 2, 21 Here, we found that ATL and ALX were required for the protective effects of aspirin in TRALI. Indeed, treatment of mice with ATL alone yielded significant protection from TRALI. These results have important clinical implications for patients with ARDS including transfused, critically ill patients. Platelet depletion is impractical, as is aspirin therapy in many critically ill patients, but treatment with ATL, or perhaps other anti-inflammatory and pro-resolving mediators, 43 is an attractive approach.
Further, the measurement of LPA in patients with ARDS and other critical illnesses could be a useful biomarker of inflammation, and could be measured serially to assess therapeutic responses to treatment with pro-resolving lipid mediators.
In summary, we have shown in two experimental models of ALI that aspirin-triggered lipoxin is a powerful inhibitor of neutrophil-and platelet-mediated lung inflammation and injury. Ironically, surface contact between neutrophil and platelets yields transcellular production of lipoxins and also leukotrienes, 45 and our results indicate that signaling through ALX on neutrophils and platelets in turn regulates their tethering during inflammation. Aspirin is likely exerting its therapeutic benefit through a combination of inhibiting the production of pro-inflammatory eicosanoids, and triggering the formation of pro-resolving lipid mediators. 46 Even low-dose dose aspirin administered to healthy volunteers is capable of producing bioactive levels of ATL, 47 
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